Vera Therapeutics Inc. has announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) through the Accelerated Approval Program for atacicept, a potential treatment for adults with immunoglobulin A nephropathy (IgAN). Atacicept, which targets both BAFF and APRIL, received FDA Breakthrough Therapy Designation and demonstrated significant proteinuria reduction in the Phase 3 ORIGIN trial. If approved, it would be the first B cell modulator of its kind for IgAN, with potential FDA approval expected in 2026. No other organizations are mentioned as recipients of grant or regulatory approval in this announcement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571777-en) on November 07, 2025, and is solely responsible for the information contained therein.